An interventional study of LHBT Transposition Augmentation in Massive Rotator Cuff Tear, sponsored by Balikesir Ataturk City Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by Balikesir Ataturk City Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Rotator Cuff Injuries with a site in Turkey — 19 open to participants now, 22 under way, none of them phase 3. Rotator Cuff Injuries · Turkey.
Among the 85 studies in Rotator Cuff Injuries with a site in Turkey, this one is the 51st largest by planned enrollment of the 63 interventional ones that give a count, is one of 13 that started in 2026, is one of 63 with no phase, reaches primary completion later than 21 of the 21 other live ones, and was the 72nd registered.
632 studies on the registry are indexed under Rotator Cuff Injuries; 157 are open to participants now.
Browse Rotator Cuff Injuries studies →19 of the 85 studies in Rotator Cuff Injuries with a site in Turkey are open now. Recruiting first, the newest first:
Istanbul Medeniyet University · Sites in Turkey
Ages 18+ · Healthy volunteers
Firat University · Sites in Turkey
Ages 18–65
Ahi Evran University Education and Research Hospital · Sites in Turkey
Ages 40–60
Istanbul Nisantasi University · Sites in Turkey
Ages 18–75
Kirsehir Ahi Evran Universitesi · Sites in Turkey
Ages 18–65
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 100 Rotator Cuff Injuries studies recruiting now, 40 (40%) set no upper age limit and 41 (41%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 13 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 35 is below the median of 60 across 456 interventional studies indexed under Rotator Cuff Injuries.
Median enrollment 44 across the 63 interventional studies, 50 across the 22 observational. Of the 58 that completed or were terminated, 1 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 85 has an industry lead sponsor. The 10 most frequent:
Balikesir Ataturk City Hospital is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Balikesir Ataturk City Hospital has 1 study filed under Rotator Cuff Injuries — fewer than ten, so there is no comparison to draw.
3 of the studies in Rotator Cuff Injuries with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07377292Ahi Evran University Education and Research HospitalEffectiveness of Core Stabilization Exercises in Rotator Cuff Injuries | 2026-12-25 |
| NCT07853950Ataturk UniversityFibrin Clot Augmentation in Arthroscopic Rotator Cuff Repair | 2027-02-28 |
| NCT07428070Istanbul Nisantasi UniversityContextually Enhanced Exercise Programs for Rotator Cuff-Related Shoulder Pain | 2027-05-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 85 studies in Rotator Cuff Injuries with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, single-arm interventional study will evaluate the effects of long head of the biceps tendon (LHBT) transposition without tenotomy as an augmentation technique for arthroscopic partial repair in adults with massive rotator cuff tears. Consecutive eligible patients undergoing arthroscopic partial rotator cuff repair plus tenotomy-sparing LHBT transposition augmentation at Balikesir City Hospital (Balikesir, Turkiye) will be enrolled and followed for 12 months. Patient-reported outcomes and clinical assessments will be collected preoperatively (baseline) and postoperatively at 3 and 12 months. The primary outcomes are shoulder function (ASES), rotator cuff-related quality of life (WORC converted to a 0-100 scale), and sleep disturbance (Insomnia Severity Index). Secondary outcomes include active shoulder range of motion and biceps-related clinical findings (Speed test, Yergason test, bicipital groove tenderness, and Popeye deformity). Postoperative MRI will not be obtained routinely and will be performed only if clinically indicated. The study aims to provide standardized prospective data on functional outcomes, quality of life, and sleep after this augmentation approach.
Detailed Description Massive rotator cuff tears may not be amenable to full anatomic repair, and even when partial repair is feasible, residual symptoms and functional limitations may persist. Long head of the biceps tendon (LHBT) transposition without tenotomy has been proposed as an augmentation strategy that may provide additional biomechanical and biologic support to arthroscopic partial rotator cuff repair. However, prospective data with standardized follow-up evaluating functional outcomes, rotator cuff-specific quality of life, and sleep outcomes remain limited. This study is designed to generate prospective, standardized clinical and patient-reported outcome data after tenotomy-sparing LHBT transposition augmentation in the setting of massive rotator cuff repair.
This is a prospective, single-arm, non-randomized interventional clinical study conducted at Balikesir City Hospital, Department of Orthopedics and Traumatology (Balikesir, Turkiye). Consecutive eligible adult patients will be enrolled between January 2026 and December 2026, with a planned sample size of 35 participants. Each participant will be followed for a minimum of 12 months. Assessments will be performed preoperatively (baseline) and postoperatively at 3 months and 12 months.
Participants and Eligibility Massive rotator cuff tear will be defined on preoperative MRI as a full-thickness tear involving at least two tendons and/or a tear with the greatest dimension greater than 5 cm. Final eligibility will be confirmed intraoperatively when the tear pattern is deemed suitable for arthroscopic partial repair with LHBT augmentation. Inclusion criteria include age 18 years or older, persistence of symptoms despite at least 3 months of standard nonoperative treatment, planned arthroscopic partial repair with LHBT augmentation, intact LHBT at the time of surgery, and willingness to attend the scheduled follow-up visits. Exclusion criteria include tear patterns not requiring augmentation (e.g., preserved rotator cable patterns), conditions affecting shoulder function (e.g., relevant neurologic disease, inflammatory arthritis), active infection, systemic conditions preventing protocol rehabilitation, inability to provide informed consent, or expected nonadherence to follow-up.
Intervention and Standardization All surgeries will be performed arthroscopically under general anesthesia (with or without interscalene block per anesthesia protocol) in the beach-chair position. Standard diagnostic glenohumeral assessment and subacromial bursectomy will be performed. Acromioplasty may be performed routinely per the surgical standard. The rotator cuff will be mobilized and partially repaired to achieve acceptable tension. For augmentation, the LHBT will be confirmed intact and will not be tenotomized. The transverse humeral ligament will be released to mobilize the tendon. The tendon will be transposed posterior to the bicipital groove and directed to the superior aspect of the greater tuberosity, avoiding overtension. Fixation will be performed to the footprint region using a standardized anchor/suture technique to create an augmentation construct supporting the partial repair. Arthroscopic assessment will confirm absence of overtension and mechanical impingement. Concomitant procedures (e.g., subscapularis repair, distal clavicle resection) will be performed only when clinically indicated and will be recorded.
Rehabilitation Protocol Postoperative management will be standardized: sling immobilization for 3 weeks; passive range of motion initiated immediately in the early postoperative period within pain limits; active range of motion starting at postoperative week 4; strengthening at approximately postoperative month 3. Biceps loading will be restricted for the first 4 weeks (no resisted elbow flexion or supination), followed by gradual progression. Rehabilitation adherence and protocol deviations will be documented.
Imaging and Intraoperative Measurements Preoperative MRI will be evaluated using the Patte classification (retraction) and Goutallier grading (fatty degeneration) by two independent assessors, with disagreements resolved by consensus. Preoperative radiographs will include Hamada classification and acromiohumeral interval (mm). Intraoperatively, tear dimensions (anteroposterior and mediolateral) will be measured using a calibrated probe at the footprint level; tear area will be recorded using a standardized practical approach (e.g., AP × ML). Routine postoperative MRI will not be performed and will be obtained only if clinically indicated (e.g., sudden strength loss, trauma, suspected failure).
Outcomes Primary outcomes are changes in ASES score, WORC score (reported on a 0-100 scale), and Insomnia Severity Index (ISI) from baseline to 3 and 12 months. WORC will be converted to a 0-100 scale using the formula: WORC (0-100) = [1 - (raw WORC / 2100)] × 100, where higher scores indicate better status. Secondary outcomes include active shoulder range of motion (forward elevation, abduction, external rotation by goniometer; internal rotation recorded using a standard method) and biceps-related clinical findings (Speed test, Yergason test, bicipital groove tenderness, Popeye deformity) assessed at baseline, 3 months, and 12 months.
Safety, Data Management, and Analysis All adverse events and complications will be recorded throughout follow-up, and clinically indicated standard care will be provided when needed. Participant data will be de-identified using unique study IDs and stored in password-protected, access-restricted electronic files. Data quality will be supported by random source verification of approximately 10% of records. Statistical analyses will use two-sided significance level of p \< 0.05. Longitudinal changes across time points (baseline, 3 months, 12 months) will be analyzed using linear mixed-effects models (time as fixed effect; participant as random intercept), with appropriate adjustment for multiple comparisons (e.g., Holm-Bonferroni). If assumptions are violated, nonparametric repeated-measures methods will be used as sensitivity analyses. Binary outcomes will be analyzed using appropriate paired/repeated methods (e.g., McNemar for two time points; mixed-effects logistic regression for three time points). Effect sizes and 95% confidence intervals will be reported, and missing data patterns will be described with complete-case sensitivity analyses.
Inclusion Criteria:
Exclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this single arm undergo arthroscopic partial rotator cuff repair augmented with tenotomy-sparing transposition of the long head of the biceps tendon (LHBT). All procedures are performed according to a standardized surgical and rehabilitation protocol.
Procedure: LHBT Transposition Augmentation
Arthroscopic partial rotator cuff repair augmented with transposition of the intact long head of the biceps tendon (LHBT) without tenotomy. The transverse humeral ligament is released to mobilize the tendon, which is transposed and fixed to the greater tuberosity footprint using a standardized anchor/suture technique to support the partial repair. Procedures are performed under a standardized surgical and postoperative rehabilitation protocol.
American Shoulder and Elbow Surgeons (ASES) Score
The ASES score is a validated patient-reported outcome measure assessing shoulder pain and function on a 0-100 scale, with higher scores indicating better shoulder function.
Time frame: aseline, 3 months, and 12 months postoperatively
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.
Of 228 non-industry interventional studies with no phase under Rotator Cuff Injuries, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's planned 20 months is close to that.
Counting every sponsor, half of 252 studies reached it within 23 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Balikesir Ataturk City Hospital